Physician profile
Nafees Khan
NPI 1548255243
$476.84
in general payments reported to CMS, 2019-2025
12 companies · $103 in 2025
The $103 reported for 2025 was more than what a typical Adolescent Medicine (Pediatrics) provider received nationally (typical 2025 total: $99.31).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.36 · 2021: $27.95 · 2022: $51.27 · 2023: $83.69 · 2024: $156 · 2025: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $343.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $136.83 | 2019-2024 | |
| Pfizer INC. | $76.76 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $66.31 | 2021-2025 | Vaxneuvance, Rotateq, Vaxelis |
| Ironshore Pharmaceuticals INC. | $65.94 | 2019-2024 | |
| Collegium Pharmaceutical, INC. | $59.49 | 2025 | Jornay Pm |
| Corium, LLC | $22.50 | 2022 | |
| Supernus Pharmaceuticals, INC. | $19.63 | 2023 | Qelbree |
| Medline Industries LP | $15.12 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.26 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nafees Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.